Feldan Therapeutics Completes a US$ 21 Million Series B financing co-led by Genesys Capital and Fonds de Solidarité Ftq

Quebec City and Toronto, Canada, September 4th, 2024 - Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, has announced the closure of a US$ 21 million Series B round co-led by Genesys Capital (Genesys) and Fonds de solidarité FTQ (Fonds).